NCT02361515View on ClinicalTrials.gov

Hypofractionated Radiotherapy Versus Stereotactic Irradiation With Hyaluronic Acid

NACompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

January 31, 2020

Study Completion Date

January 31, 2020

Conditions
Prostatic Adenocarcinoma
Interventions
RADIATION

Moderate hypofractionated radiotherapy

Moderate hypofractionated radiotherapy of 62Gy in 20 fraction of 3.1Gy.

RADIATION

Stereotactic radiotherapy

Stereotactic radiotherapy of 37.5Gy in 5 fraction of 7.5Gy.

Trial Locations (7)

13009

Institut Paoli Calmettes, Marseille

21079

Centre Georges Francois Leclerc, Dijon

31300

Groupe ONCORAD Clinique Pasteur, Toulouse

42270

Institut de Cancérologie de la Loire, Saint-Etienne

44805

Site Hospitalier Nord Boulevard Jacques Monod, Nantes

69495

Centre Hospitalier Lyon Sud, Pierre-Bénite

81000

Clinique Claude Bernard Service de radiothérapie CMCO Claude Bernard, Albi

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT02361515 - Hypofractionated Radiotherapy Versus Stereotactic Irradiation With Hyaluronic Acid | Biotech Hunter | Biotech Hunter